Mosunetuzumab

CHEMBL4297788 Phase 4 Approved Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This bispecific antibody simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T cells, forcing the immune system's killer T cells into direct contact with cancer cells to destroy them. It offers a fixed-duration treatment option for patients with relapsed or refractory follicular lymphoma.

Therapeutic Areas

Immunology Lymphoma Oncology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

This bispecific antibody simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T cells, forcing the immune system's killer T cells into direct contact with cancer cells to destroy them. It offers a fixed-duration treatment option for patients with relapsed or refractory follicular lymphoma.

Yes, Mosunetuzumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297788. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

Looking for patient-friendly information?

Mosunetuzumab on PillFYI

Quick Data

Synonyms: 2

External Links

ChEMBL CHEMBL4297788

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.